Palmitoyl tripeptide-1 is one of the most widely formulated cosmetic peptides in the world and one of the least studied under its own name. This entry counts what has actually been published about it, names what each record can and cannot show, and separates it from the molecule whose research it is most often credited with.
What the molecule is
Strip the marketing and it is a short peptide with a fatty tail. The peptide is glycyl-L-histidyl-L-lysine — GHK, three amino acids. The tail is palmitic acid, and it is there for one reason: GHK is hydrophilic, the outer layer of skin is not, and a water-loving molecule that cannot cross the barrier has no route to the fibroblasts it is supposed to act on. Palmitoylation makes it more lipophilic. That is the design.
The same GHK core turns up elsewhere in this field carrying a copper ion instead of a fatty acid, and that version is the copper peptide. One sequence, two very different finished molecules — a distinction that matters because the research does not transfer between them.
The census
Searched on 2026-09-09, PubMed holds 8 records for palmitoyl tripeptide-1. That number is small enough to describe individually, which is the useful thing about a literature this size:
| What it is | How many |
|---|---|
| Analytical-chemistry methods (measuring palmitoyl peptides in cosmetics, 2009; lipid complexing, 1999) | 2 |
| Cell-line work (melanin production in A375 and B16 lines) | 1 |
| Computational screening (knowledge-graph peptide screening for type III collagen, 2026) | 1 |
| Review of the parent molecule GHK | 1 |
| Combination-product clinical assessments (an eye cream; a lip treatment, 2009) | 2 |
| Circadian-rhythm collagen paper | 1 |
Not one of them is a trial of palmitoyl tripeptide-1 on its own.
The trade name does worse. A search for Matrixyl 3000 returns 0 PubMed records — the brand under which most of this ingredient reaches consumers has no literature under that name at all. The blend's other peptide, palmitoyl tetrapeptide-7, returns 5.
By way of scale in the other direction: GHK crossed with skin returns 66 records. The parent has eight times the science of the derivative sold on its reputation.
To check that these small numbers were real rather than a broken query, the same session ran a control with a known answer — minoxidil crossed with alopecia under the randomised-controlled-trial filter — which returned 149. The query shape works. The counts are the counts.
The one randomised study, read properly
Exactly one of the eight records carries PubMed's randomised-controlled-trial tag: a 2024 paper in Skin Research and Technology evaluating a new multi-component anti-aging eye cream over 12 weeks, with hydration, elasticity, photography and ultrasound collagen density as outcomes. The reported results are substantial — hydration up 28.12%, elasticity up 18.81%, collagen up 54.99%.
Three things about it decide how much weight it carries, and all three are in the paper.
It tests four actives at once. The complex is yeast/rice fermentation filtrate, N-acetylneuraminic acid, palmityl tripeptide-1 and palmitoyl tetrapeptide-7. Whatever the cream did, the study cannot say which ingredient did it. This is the ordinary shape of cosmetic evidence, and it is why a peptide can be in a successful trial without being tested.
The abstract names no control arm. Outcomes are reported after 12 weeks of application. Skin hydration and elasticity respond to occlusion and to regular moisturising almost regardless of what else is in the jar, so a before-and-after on those measures is the least discriminating design available.
The provenance is worth stating plainly. Four of the ten authors are listed at the Research and Development Center of Mageline Biology Tech Co., Ltd. The paper's conflict-of-interest statement reads that no conflict of interest was reported by the authors. Both facts are printed in the paper; we report them and leave the reader to weigh them.
What the field says about its own evidence
The most useful record among the eight is the review, because it reaches the same conclusion from inside the discipline. Assessing topically applied GHK and its two commercial derivatives, the authors write that although GHK-Cu and Pal-GHK "are widely used in anti-wrinkle products available on the cosmetic market, the published information on their skin permeability, effectiveness, physicochemical properties and so on is insufficient", and that there is "a surprising absence of clinical studies using them". Their assessment of the cell-level work is genuinely positive — GHK does what it is said to do to fibroblasts in a dish. The gap is between that and a finished product on a face.
The arithmetic that cannot be completed
On other ingredient pages here, the useful move is to convert a label claim into a peptide concentration. That works when the supplier publishes the strength of the raw material: the SNAP-8 sheet states 0.05% active, so a product carrying 10% of that solution contains about 0.005% peptide.
That conversion is not available for this ingredient. Public sources give the recommended use level of the Matrixyl 3000 blend as roughly 3 to 8 percent, and we could not obtain a supplier document stating what proportion of the blend is peptide. The consequence is worth stating rather than glossing: a percentage on a Matrixyl 3000 product describes the blend, not the peptide, and the two cannot be converted from published information. A higher number on the front of the bottle is not a demonstrated higher dose of anything.
Where this leaves the ingredient
Palmitoyl tripeptide-1 has a coherent mechanism, a plausible reason for its fatty tail, encouraging cell-level data on the molecule it is built from, and no clinical trial of itself. That combination is common in cosmetic chemistry and is not the same as a debunking. It does mean that a product page citing "clinical studies" for this peptide is almost certainly citing a study of a formula, of the parent molecule, or of nothing published at all.
The neighbouring entries here — Argireline, Matrixyl and SNAP-8 — are counted the same way, and the pattern across all four is that the size of an ingredient's marketing has no relationship to the size of its literature.
Sources and dates
All searched or accessed 2026-09-09. PubMed record counts via the E-utilities API for palmitoyl tripeptide-1 (8), the quoted-phrase form (16), Matrixyl 3000 (0), palmitoyl tetrapeptide-7 (5) and GHK crossed with skin (66), with minoxidil crossed with alopecia under the randomised-controlled-trial filter (149) as a control query. Yang et al., "Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream", Skin Research and Technology 2024 (PMID 38932444). Mortazavi et al., "Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective", Bioimpacts 2025 (PMID 39963574). Blend use levels are from secondary formulation sources and are reported as such because no supplier datasheet could be obtained. Corrections go to the contact page.